135 related articles for article (PubMed ID: 2495717)
1. Elevated urokinase-type plasminogen activator level and bleeding in amyloidosis: case report and literature review.
Sane DC; Pizzo SV; Greenberg CS
Am J Hematol; 1989 May; 31(1):53-7. PubMed ID: 2495717
[TBL] [Abstract][Full Text] [Related]
2. Excessive fibrinolysis in amyloidosis associated with elevated plasma single-chain urokinase.
Liebman HA; Carfagno MK; Weitz IC; Berard P; Diiorio JM; Vosburgh E; Simms RW
Am J Clin Pathol; 1992 Nov; 98(5):534-41. PubMed ID: 1485607
[TBL] [Abstract][Full Text] [Related]
3. Differences between neonates and adults in the urokinase-plasminogen activator (u-PA) pathway of the fibrinolytic system.
Ries M; Zenker M; Gaffney PJ
Thromb Res; 2000 Nov; 100(4):341-51. PubMed ID: 11113278
[TBL] [Abstract][Full Text] [Related]
4. Urokinase-like plasminogen activator increased in plasma after alcohol drinking.
Sumi H; Hamada H; Tsushima H; Mihara H
Alcohol Alcohol; 1988; 23(1):33-43. PubMed ID: 3128990
[TBL] [Abstract][Full Text] [Related]
5. Fibrinolysis and acquired alpha-2 plasmin inhibitor deficiency in amyloidosis.
Meyer K; Williams EC
Am J Med; 1985 Sep; 79(3):394-6. PubMed ID: 4036990
[TBL] [Abstract][Full Text] [Related]
6. The bleeding disorder in acute promyelocytic leukaemia: fibrinolysis due to u-PA rather than defibrination.
Bennett B; Booth NA; Croll A; Dawson AA
Br J Haematol; 1989 Apr; 71(4):511-7. PubMed ID: 2496742
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
8. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor.
Schleef RR; Higgins DL; Pillemer E; Levitt LJ
J Clin Invest; 1989 May; 83(5):1747-52. PubMed ID: 2496147
[TBL] [Abstract][Full Text] [Related]
9. [Clinical significance of the fibrinolysis system].
Himmelreich G; Riess H
Dtsch Med Wochenschr; 1991 Mar; 116(11):426-30. PubMed ID: 1900466
[No Abstract] [Full Text] [Related]
10. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
Watahiki Y; Scully MF; Ellis V; Kakkar VV
Thromb Haemost; 1989 Jun; 61(3):502-6. PubMed ID: 2508259
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator.
Booth NA; Anderson JA; Bennett B
J Clin Pathol; 1984 Jul; 37(7):772-7. PubMed ID: 6235248
[TBL] [Abstract][Full Text] [Related]
12. Pathologic hyperfibrinolysis associated with amyloidosis: clinical response to epsilon amino caproic acid.
Chang JC; Kane KK
Am J Clin Pathol; 1984 Mar; 81(3):382-7. PubMed ID: 6702732
[TBL] [Abstract][Full Text] [Related]
13. Fibrinolysis and coagulation in patients with infectious disease and sepsis.
Philippé J; Offner F; Declerck PJ; Leroux-Roels G; Vogelaers D; Baele G; Collen D
Thromb Haemost; 1991 Mar; 65(3):291-5. PubMed ID: 1904655
[TBL] [Abstract][Full Text] [Related]
14. [Urokinase as a blood and urine plasminogen activator in chronic glomerulonephritis and amyloidosis].
Andreenko GV; Poliantseva LR; Podorol'skaia LV; Bumblite ID
Vestn Ross Akad Med Nauk; 1999; (2):58-61. PubMed ID: 10204025
[TBL] [Abstract][Full Text] [Related]
15. Changes in urokinase-type plasminogen activator in orthotopic liver transplantation.
Himmelreich G; Dooijewaard G; Breinl P; Bechstein WO; Blumhardt G; Kluft C; Riess H
Semin Thromb Hemost; 1993; 19(3):311-4. PubMed ID: 7689759
[TBL] [Abstract][Full Text] [Related]
16. Excessive fibrinolysis in suspected amyloidosis: demonstration of plasmin-alpha 2-plasmin inhibitor complex and von Willebrand factor fragment in plasma.
Takahashi H; Koike T; Yoshida N; Kitahara O; Hanano M; Shibata A; Aoki N
Am J Hematol; 1986 Oct; 23(2):153-66. PubMed ID: 2944378
[TBL] [Abstract][Full Text] [Related]
17. Physical exercise induces enhancement of urokinase-type plasminogen activator (u-PA) levels in plasma.
Dooijewaard G; de Boer A; Turion PN; Cohen AF; Breimer DD; Kluft C
Thromb Haemost; 1991 Jan; 65(1):82-6. PubMed ID: 1902597
[TBL] [Abstract][Full Text] [Related]
18. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
19. Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.
Lijnen HR; Dewerchin M; De Cock F; Collen D
Thromb Res; 1990 Feb; 57(3):333-42. PubMed ID: 2107593
[TBL] [Abstract][Full Text] [Related]
20. Fibrin-specific thrombolytic agents.
Collen D
Schweiz Med Wochenschr; 1987 Nov; 117(46):1791-8. PubMed ID: 3122317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
